DARA Biosciences (NASDAQ: DARA) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.
This table compares DARA Biosciences and TherapeuticsMD’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares DARA Biosciences and TherapeuticsMD’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|TherapeuticsMD||$19.36 million||74.00||-$89.87 million||($0.40)||-16.55|
DARA Biosciences has higher earnings, but lower revenue than TherapeuticsMD. TherapeuticsMD is trading at a lower price-to-earnings ratio than DARA Biosciences, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
73.8% of TherapeuticsMD shares are held by institutional investors. 23.9% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for DARA Biosciences and TherapeuticsMD, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TherapeuticsMD has a consensus price target of $15.00, suggesting a potential upside of 126.59%. Given TherapeuticsMD’s higher probable upside, analysts plainly believe TherapeuticsMD is more favorable than DARA Biosciences.
Volatility & Risk
DARA Biosciences has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500.
TherapeuticsMD beats DARA Biosciences on 9 of the 10 factors compared between the two stocks.
About DARA Biosciences
DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company’s primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.
TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.
Receive News & Ratings for DARA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DARA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.